11:56 a.m. EST:
Amgen’s sotorasib news could be its all time high.
Immediately following that announcement, AMGN went into a 20% decline (‘sign of supply’).
In Wyckoff terms, we can look at the action from late January to now as a massive ‘up-thrust’ (false breakout).
That up-thrust is now being tested … with another breakout attempt.
If that’s the case and the test fails with price action retreating from here, then AMGN’s set-up for a significant downward reversal.
Significant in that we’re not (ever) coming back to these levels.
That statement might seem hyperbolic and it very well could be.
However, when one looks at reports like this, insiders are bailing out; leaving “retail” holding the bag as usual.
Although not directly related to AMGN, we have yet another horror show in the biotech arena.
The wheels are falling off the ‘speck’ false narrative; tragically so.
The following is taken from the comment section of the video post:
From the guy who filmed :
“Less than 5 minutes from getting God knows what injected inside them the two people to my left starting having seizures. First the gentlemen in the red car was watching in shock as the driver next to him was having a seizure. Little did he know he would have one right after him. I called the medics to help him. They have a procedure where after you get the shot you have to wait in the car for 15 min and if something goes wrong to honk your horn and someone will show up. Well these folks to my left just passed out into seizures with no warning.
You would think it’s just a matter of time before this reaches some kind of tipping point; where enough of the herd realizes all at once, the lie.
The last post has us breaking the rules. Was that the right thing to do?
This morning’s price action has the answer: Yes.
The Project Stimulus table has been updated to include the new (hard) stop level. With LABD currently up a good 5.50%, and looking to move higher, it’s not likely the stop will be hit.
There is one caveat: As of this post, IBB has not printed a new daily low. That leaves the (slight) possibility open for a move higher.
Several attempts have been made to short biotech via LABD (not advice, not a recommendation). It looks like the current attempt is underway.
Charts by StockCharts